Tyra Biosciences, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Tyra Biosciences, Inc. (TYRA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $6.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $5.32M.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.20M.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $2.16M, a 2.36% decline year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $2.07M, a 2.83% increase year-over-year.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $3.37M.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$744.00K, a 107.94% decline from fiscal 2023.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $9.37M, a 297.50% increase from fiscal 2022.
- Tyra Biosciences, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.36M, a 57.98% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.51M 10-Q · filed 2026-08-04 | $8.67M derived: sum of 3 quarters · filed 2026-08-04 | $10.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-13 | $3.35M derived: sum of 2 quarters · filed 2026-05-13 | $5.42M derived: sum of 3 quarters · filed 2026-05-13 | $4.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.22M derived: sum of 2 quarters · filed 2026-03-02 | $3.73M derived: sum of 3 quarters · filed 2026-08-04 | $3.37M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.58M derived: sum of 2 quarters · filed 2026-08-04 | $1.21M 10-Q · filed 2025-11-05 | $3.42M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$491.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$856.00K 10-Q · filed 2026-08-04 | $1.35M derived: sum of 3 quarters · filed 2026-08-04 | $3.36M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$365.00K 10-Q · filed 2026-05-13 | $1.84M derived: sum of 2 quarters · filed 2026-05-13 | $3.85M derived: sum of 3 quarters · filed 2026-05-13 | $5.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.22M derived: sum of 2 quarters · filed 2026-03-02 | $6.16M derived: sum of 3 quarters · filed 2026-03-02 | -$744.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.95M derived: sum of 2 quarters · filed 2025-11-05 | -$2.95M 10-Q · filed 2025-11-05 | $2.12M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.96M 10-Q · filed 2025-08-14 | $112.00K derived: sum of 3 quarters · filed 2025-08-14 | $4.75M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$6.91M 10-Q · filed 2025-05-08 | -$1.83M derived: sum of 2 quarters · filed 2025-05-08 | $2.81M derived: sum of 3 quarters · filed 2025-05-08 | $4.49M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $9.72M derived: sum of 2 quarters · filed 2025-03-27 | $11.39M derived: sum of 3 quarters · filed 2025-03-27 | $9.37M 10-K · filed 2025-03-27 |
| 2023-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.32M derived: sum of 2 quarters · filed 2024-11-07 | $4.29M 10-Q · filed 2024-11-07 | $4.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$350.00K 10-Q · filed 2024-08-07 | -$143.00K derived: sum of 3 quarters · filed 2024-08-07 | -$95.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$2.02M 10-Q · filed 2024-05-09 | -$1.81M derived: sum of 2 quarters · filed 2024-05-09 | -$1.77M derived: sum of 3 quarters · filed 2024-05-09 | -$1.23M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $255.00K derived: sum of 2 quarters · filed 2024-03-19 | $797.00K derived: sum of 3 quarters · filed 2024-03-19 | $2.36M 10-K · filed 2024-03-19 |
| 2022-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $590.00K derived: sum of 2 quarters · filed 2023-11-07 | $2.15M 10-Q · filed 2023-11-07 | $2.25M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $542.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.10M 10-Q · filed 2023-08-10 | $2.20M derived: sum of 3 quarters · filed 2023-08-10 | $3.42M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.56M 10-Q · filed 2023-05-04 | $1.66M derived: sum of 2 quarters · filed 2023-05-04 | $2.88M derived: sum of 3 quarters · filed 2023-05-04 | $3.63M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.32M derived: sum of 2 quarters · filed 2023-03-22 | $2.07M derived: sum of 3 quarters · filed 2023-03-22 | $1.49M 10-K · filed 2023-03-22 |
| 2021-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.97M derived: sum of 2 quarters · filed 2022-11-03 | $1.40M 10-Q · filed 2022-11-03 | $2.36M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $745.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $171.00K 10-Q · filed 2022-08-04 | $1.13M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$574.00K 10-Q · filed 2022-05-05 | $386.00K derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.02M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $59.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |